5:38 PM
 | 
Apr 02, 2013
 |  BC Extra  |  Top Story

IQWiG backs Eliquis for additional indication

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Eliquis apixaban from Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) has "significant" additional benefit to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation (AF) with one or more risk factors -- an indication...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >